Tag Archives: CD68+

CARMA – Chimeric Antigen Receptor Macrophages

CARMA Therapeutics, a company that develops chimeric antigen receptor technology, not for T-cells (CAR-T cells), rather, for macrophages, hence the name “CARMA,” closed on an initial round of funding to advance its technologies. Continue reading